
Report ID: SQSG35B2013
Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Prefilled Syringes Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Prefilled Syringes industry players.
The prefilled syringes market is particularly competitive and dynamic, with each installed pharmaceutical giants and specialized medical tool agencies actively engaged in driving innovation, enhancing patient safety, and increasing their international presence. These competitive environments are fashioned by way of elements such as technological advancements, strategic partnerships, acquisitions, and the consistent need for addressing stringent regulatory requirements.
REQUEST FOR SAMPLE
Prefilled Syringes Market size was valued at USD 7.52 Billion in 2023 and is poised to grow from USD 8.32 Billion in 2024 to USD 18.63 Billion by 2032, growing at a CAGR of 10.60% during the forecast period (2025-2032).
The prefilled syringes market is particularly competitive and dynamic, with each installed pharmaceutical giants and specialized medical tool agencies actively engaged in driving innovation, enhancing patient safety, and increasing their international presence. These competitive environments are fashioned by way of elements such as technological advancements, strategic partnerships, acquisitions, and the consistent need for addressing stringent regulatory requirements. 'BD (US) ', 'Gerresheimer AG (Germany) ', 'SCHOTT (Germany) ', 'West Pharmaceutical Services, Inc. (US) ', 'AptarGroup, Inc. (US) ', 'Nipro (Japan) ', 'Baxter (Simtra) (US) ', 'Owen Mumford Ltd. (UK) ', 'Weigao Medical International Co., Ltd. (China) ', 'Credence MedSystems, Inc. (US) ', 'Novartis AG (Switzerland) ', 'Stevanato Group (Italy) ', 'Poly Medicure (India) ', 'MedXL Inc. (Canada) ', 'Sharps Technology, Inc. (US) ', 'Fresenius Kabi USA (US) ', 'Medefil, Inc. (US) ', 'D.B.M. S.R.L. (Italy) ', 'Taisei Kako Co., Ltd. (Japan) ', 'Shandong Province Medicinal Glass Co., Ltd. (China) ', 'Shin Yan Sheno Precision Industrial Co., Ltd. (Taiwan) ', 'J.O. Pharma Co., Ltd. (Otsuka Holdings Co., Ltd.) (Japan) ', 'BMI Korea (South Korea) ', 'Al Shifa Medical Products Co. (Saudi Arabia)'
Increasing incidence of chronic diseases such as diabetes mellitus, rheumatoid arthritis and rheumatoid arthritis has created demand for vaccines which are commonly administered by injection has increased dramatically. The demand for prefilled syringes has been amplified. The power of a syringe a controlled packaging can reduce the risk of contamination and minimize dose errors makes it the best option for vaccines and therapeutics strong application in nature, leading to market growth.
Traditionally glass has been the preferred material for prefilled syringes, due to its inertness and compatibility with a wide range of chemicals but polymer-based prefilled syringes are gaining popularity. Polymeric materials such as cyclic olefin polymers (COP) and cyclic olefin copolymers (COCs) increase strength and reduce the risk of contamination from glass breakage. These materials are particularly useful for biologics and complex pharmaceuticals requiring accurate and robust quantification. The trend toward polymer-based syringes is expected to increase as pharmaceutical companies seek safer and more durable products than glass.
North America region in the prefilled syringes market share is 32.3% in 2023. Prevention of needlestick injuries by healthcare professionals is a priority in developed countries including the US. and Canada including in pre-filled syringes with needle guards decrease the likelihood of this injury. Centers for Disease Control for Vaccine Administration owing to their ability to preserve vaccine potency over a long period of time and shelf life driving the market growth. North America accounted for the largest share of the pre-filled syringes market in 2023. Also, injection devices, improved medication regimens, technological advances, routine prescriptions of self-administered devices and Prevention (CDC) recommendations are expected to deliver the market has developed.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQSG35B2013
[email protected]
USA +1 351-333-4748